Press Releases

Web Summit: MedTech Biome Diagnostics Wins Startup Audience Award

By November 8, 2022No Comments

Austrian MedTech Biome Diagnostics convinces investor jury and audience

Vienna, November 7, 2022 – Biome Diagnostics reaches second place in the Startup competition at the Web Summit in Lisbon and wins the public vote with 56 percent of the votes. The Web Summit is one of the most important and largest tech conferences in Europe. Around 2,000 young companies presented their technologies and business models in front of international investors. The approach and vision of Dr. Nikolaus Gasche, Founder and Managing Director of Biome Diagnostics, made it to the top 2 of the most successful pitches and convinced not only the jury, but also the majority of the tech experts on site.

I am simply overwhelmed. In this atmosphere of the Web Summit, to be among the last three founders in the startup competition means a lot to us. Not only to prevail against 2,000 competitors, but also to be able to continue our mission of promoting technological progress in precision medicine in an understandable and convincing way. In front of a crowd of more than 20,000 guests in the Arena – including many investors and customers – it is therefore a very special milestone in our mission to develop first-class microbiome diagnostics and therapeutics that can be used by clinicians in routine care. I am grateful to our supporters for getting us to this point. And we will continue on this path with confidence.

Dr. Nikolaus Gasche on the top 2 ranking

Biome Diagnostics GmbH was founded in 2018 and is an Austria-based MedTech company. It analyzes the gut microbiome with the goal of improving cancer treatment and therapy. Its first product is BiomeOne┬«, the world’s first and only stool-based predictive test for response to immunotherapy in cancer treatment. A single stool sample is sufficient to perform a thorough DNA analysis and determine how the patient will respond to the planned immunotherapy. The analytical accuracy of the data regarding the probability of response or non-response to cancer immunotherapy is currently > 90 percent. The method also provides information on the severity of expected side effects. BiomeOne┬« has been available on the market since August 2022. Further products will follow in the coming months, including a significantly improved method for the early detection of colorectal cancer.

The company is thus strategically positioned at the intersection of state-of-the-art DNA-sequencing and advanced machine learning algorithms to deliver best-in-class technologies for routine clinical diagnostics. Biome Diagnostics already has more than 25,000 datasets of analyzed gut microbiome profiles by 2022. It is also the first microbiome company in the world to be certified according to ISO 13485:2016 and ISO 9001:2015 and is already one of the fastest growing companies in microbiome diagnostics.